Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

EU regulator starts a review of Russia's COVID-19 vaccine

The European Medicines Agency said it has started a rolling review of Sputnik V, many months after the vaccine was first approved for use in Russia and after dozens of countries around the world have authorized it

Via AP news wire
Thursday 04 March 2021 10:18 GMT
Virus Outbreak Slovakia Sputnik V
Virus Outbreak Slovakia Sputnik V

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

The European Medicines Agency said it has started a rolling review of Sputnik V, many months after the vaccine was first approved for use in Russia and after dozens of countries around the world have authorized it.

In a statement Thursday, the European regulator said the review is based on results from lab studies and research in adults, which suggests the vaccine may help protect against coronavirus.

Despite skepticism about Russia’s hasty introduction of the vaccine, which was rolled out before it had completed late-stage trials, the vaccine appears to be safe and effective. According to a study published in the journal Lancet, Sputnik V was about 91% effective in preventing people from becoming severely ill with COVID-19

The EMA has not set a date for when its expert group might meet to assess Sputnik V data to decide if it should be approved across the European Union, but the rolling review process is meant to expedite the authorization process, which can typically take several months.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in